aumolertinib,osimertinib
eqrx,jiangsu hengrui pharmaceuticals,astrazeneca
['lcsm,(-blcsm)', 'lung', 'osimertinib', 'aumolertinib', 'eqrx']
very interested in following 's potentially lower cost aumolertinib, which showed superior cns efficacy over gefitinib in 1l egfr+ #lungcancer. next study will be a head-to-head comparison of aumolertinib vs. osimertinib in china. #lcsm #asco22 
Co-Founder, @EGFRResisters LC Patient Group; writer for https://t.co/W6HLnN0ibZ; lc advocate/survivor; dx stage IV 2013
https://t.co/2UwibVmlPs